Development Pipeline
  Commercial Products
  Research Programs







Product: Remoxy®
NDA
Indication: Chronic Pain
Drug: Oxycodone
Partner: Pfizer and Pain Therapeutics
Technology: ORADUR® (sustained release oral gel-cap)

Product: POSIDUR™
Phase II
Indication: Post-Operative Pain
Drug: Bupivacaine
Partner: Worlwide rights held by DURECT
Technology: SABER® Delivery System (injectable)

Product: TRANSDUR®-Sufentanil
Phase I
Indication: Chronic Pain
Drug: Sufentanil
Partner: Worldwide rights held by DURECT
Technology: TRANSDUR Delivery System

Product: ELADUR® (TRANSDUR®-Bupivacaine)
Phase I
Indication: Post-Herpetic Neuralgia
Drug: Bupivacaine
Partner: Impax
Technology: TRANSDUR Delivery System

Product: ORADUR-based Opioids #2 and #3
Phase I
Indication: Chronic Pain
Drug: Hydrocodone and Hydromorphone
Partner: Pain Therapeutics
Technology: ORADUR® (sustained release oral gel-cap)

Product: ORADUR®-ADHD
Phase I
Indication: Attention Deficit Hyperactivity Disorder
Drug: Undisclosed
Partner: Orient Pharma (certain Asian countries)
Technology: ORADUR® (sustained release oral gel-cap)

Product: Relday™ (risperidone)
Phase I
Indication: Schizophrenia and Bipolar Disorder
Drug: Risperidone
Partner: Zogenix
Technology: SABER Delivery System



 
 © 2000-2014 DURECT Corporation
Last updated: October 16, 2014
Search     Contact     Site Index     Legal Notice     Privacy Policy